Arrowhead Pharmaceuticals, Inc. (ARWR) Covered Calls
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases by silencing genes that cause them. Utilizing a proprietary RNA interference (RNAi) platform, the company creates therapies that trigger the natural gene-silencing machinery of the cell. Its pipeline focuses on treating diverse conditions, including liver disease, cardiovascular disease, and pulmonary disorders, through targeted delivery and innovative genetic medicine.
You can sell covered calls on Arrowhead Pharmaceuticals, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ARWR (prices last updated Fri 4:16 PM ET):
| Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 73.91 | -0.49 | 73.13 | 75.75 | 1.6M | 49 | 10 |
| Covered Calls For Arrowhead Pharmaceuticals, Inc. (ARWR) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 15 | 75 | 3.70 | 72.05 | 4.1% | 68.0% | |
| Jun 18 | 75 | 6.00 | 69.75 | 7.5% | 48.9% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Arrowhead Pharmaceuticals is a pioneer in the field of RNA interference (RNAi) therapeutics. The company utilizes its proprietary Targeted RNAi Molecule (TRiM) platform to develop medicines that target the genetic source of diseases. By silencing specific genes, Arrowhead aims to treat conditions that are poorly addressed by traditional small molecule or antibody-based drugs.
The company recently achieved a major milestone with its first commercial product, plozasiran, designed to treat familial chylomicronemia syndrome. Its broader pipeline includes promising candidates for cardiovascular health, such as therapies targeting triglycerides and cholesterol. Arrowhead is also advancing programs in metabolic diseases, liver-targeted therapies, and treatments for respiratory and central nervous system disorders.
Competitive Landscape
The genetic medicine and RNAi space is highly competitive, featuring established biotech leaders and innovative newcomers. Success in this field depends on the efficiency of delivery systems, the duration of gene silencing effects, and the safety profile of the treatment. Arrowhead differentiates itself through its TRiM platform, which allows for highly specific tissue targeting.
Key competitors in the RNAi and rare disease markets include:
- Alnylam Pharmaceuticals: A primary leader in the RNAi space with multiple approved therapies on the market.
- Ionis Pharmaceuticals: A major competitor focusing on antisense technology to achieve similar gene-silencing results.
- Ultragenyx Pharmaceutical: Specializes in the development of novel products for rare and ultra-rare genetic diseases.
- Sarepta Therapeutics: Focused on precision genetic medicines for rare neuromuscular and central nervous system disorders.
Strategic Outlook and Innovation
Arrowhead is transitioning from a research-focused organization into a commercial-stage biopharmaceutical company. This evolution is driven by the expansion of its platform into extra-hepatic tissues, including the lungs and brain. By diversifying its delivery capabilities, the company aims to address a wider range of chronic and rare diseases that were previously unreachable by RNAi technology.
The company continues to pursue strategic collaborations with larger pharmaceutical firms to accelerate the development and global distribution of its candidates. Ongoing research efforts are focused on improving the potency of its molecules and reducing the frequency of dosing. This long-term innovation strategy is designed to provide patients with more convenient and effective options for managing genetic conditions.
| Top 10 Open Interest For May 15 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | TLT covered calls | 1. | POET covered calls | |
| 2. | SLV covered calls | 7. | HYG covered calls | 2. | CMPX covered calls | |
| 3. | IBIT covered calls | 8. | QQQ covered calls | 3. | TEAM covered calls | |
| 4. | GLD covered calls | 9. | KWEB covered calls | 4. | AAOI covered calls | |
| 5. | SPY covered calls | 10. | EEM covered calls | 5. | ENPH covered calls | |
Want more examples? ARW Covered Calls | ARX Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
